Sirtex shareholders to vote on acquisition

Latest News

Sirtex Medical (ASX:SRX) has announced that the Federal Court of Australia has made orders approving the despatch of the scheme booklet in relation to its proposed acquisition.

The Australian cancer company recently announced it has accepted a $1.9 billion takeover bid from Chinese company CDH Genetech.

The acquisition will be by way of scheme of arrangement. The court has ordered that a meeting of Sirtex shareholders be convened to consider and vote on the scheme. The meeting will be held in Sydney on 10 September 2018 at the Royal Automobile Club of Australia.

"All Sirtex shareholders are encouraged to vote either by attending the Scheme Meeting in person, or by lodging a proxy form with the Sirtex share registry by 10.00am (Sydney time) on Saturday, 8 September 2018, being not later than 48 hours before the commencement of the Scheme Meeting," said the company.

"The Independent Expert appointed by the Board of Directors of Sirtex in relation to the Scheme, Deloitte Corporate Finance Pty Limited (Deloitte), has concluded that the Scheme is fair and reasonable and therefore in the best interests of Sirtex shareholders," it added.

The company said its Board continues to "unanimously recommend" that shareholders vote in favour of the scheme.